Lessons from animal models of arthritis over the past decade. by Berg, W.B. van den
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/79982
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Available online http://arthritis-research.com/content/11/5/250
Review
Lessons from animal models of arthritis over the past decade
Wim B van den Berg
Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, The Netherlands
Corresponding author: Wim B van den Berg, w.vandenberg@reuma.umcn.nl
Published: 14 October 2009 Arthritis Research & Therapy 2009, 11:250 (doi:10.1186/ar2803)
This article is online at http://arthritis-research.com/content/11/5/250 
© 2009 BioMed Central Ltd
Abstract
This review summarizes the major developments in animal models 
of arthritis in the past decade. It focuses on novel transgenic 
models, addresses the involvement of cytokines and discusses 
novel findings in cartilage and bone erosion. It is clear that interest 
has been raised in the direct arthritogenic role of autoantibodies, 
apart from T cell involvement, and their interaction with cells 
through Fcgamma receptors. In addition, a role for IL-6 and IL-17 
and Th17 cells seems apparent in most T cell-driven arthritis 
models, with environmental triggering through Toll-like receptors 
contributing to this process. Further insights into enzymes involved 
in cartilage proteoglycan loss in arthritis, as well as mediators 
regulating bone erosion and bone apposition, have been gained.
Introduction
Animal models have contributed to the understanding of 
basic mechanisms of jo int disease. There is marked diversity 
among the numerous models, and arthritis has been induced 
by various stimuli. These include the generation of auto­
immunity to cartilage com ponents, nonspecific skew ing of 
autoimmunity w ith  adjuvants, and triggering w ith exogenous 
agents such as bacteria and viruses. M ore recently, focused 
transgenic manipulation has added novel variants (Table 1).
The w ide variety of agents that can induce experimental 
arthritis w ith  histopathological features close to those of 
human arthritides suggests that disparate etio logical path­
ways may exist in rheumatoid arthritis (RA). No single animal 
model of arthritis truly represents the human disease, but the 
m odels m im ic various aspects and can be used as tools to 
understand particular pathways.
Developm ents over the past decade include the generation of 
novel models as well as pathway analysis and therapeutic 
targeting in classic models. A spects peculiar to individual 
m odels are of value but must be interpreted w ith caution. 
M uch can be learned from the general validity of m ediator
involvement and other common concepts. This review will not 
discuss the developm ents in immune regulation and the use 
of models to identify disease susceptib ility genes, but will 
focus on insights into cytokine involvement and aspects of 
jo int destruction. The process of cartilage erosion remains 
hard to evaluate in patients. Synovial biopsies are now 
performed in many early arthritis clinics, but samples of 
damaged bone and cartilage become available only late in the 
disease, after jo int replacement. M odels therefore provide 
valuable tools.
Characteristic histopathological features of R A  include 
immune complexes (IC s) in the articular cartilage layers and 
variable amounts of macrophages, T cells and plasma cells in 
the synovium, often accom panied by fibrosis and synovial 
hyperplasia. Formation of autoantibodies, including rheuma­
toid factor and the more recently discovered anti-citrulline or 
anti-citrullinated protein antibodies (ACPAs), is prominent, 
making B  cell activation and IC-m ediated cellular inflam­
mation likely contributors to pathogenesis. Indeed, 
perceptions have changed over the years and it is now 
generally accepted that IC  arthritis m odels have their value 
and are increasingly used, although it must be emphasized 
that erosive arthritis is only achieved w ith high amounts of 
defined antibody cocktails. In fact, chronicity and joint 
erosions of IC  arthritis are markedly amplified by the presence 
of a T cell component.
Models of arthritis
From a historical perspective, the models most w idely used in 
the past decades have been adjuvant arthritis, collagen- 
induced arthritis (CIA), antigen-induced arthritis (A IA) and 
streptococcal cell wall arthritis (Table 1). These m odels are 
classic examples of three driving elements: nonspecific 
immune deviation, targeted cartilage autoimmunity and 
abundant exogenous/infectious triggers. T cells play a
ACPA =  anti-citrullinated protein antibody; AIA =  antigen-induced arthritis; CIA =  collagen-induced arthritis; FcgR =  Fcgamma receptor; GPI =  
glucose-6-phosphate isomerase; IC =  immune complex; IFN =  interferon; IL =  interleukin; RA =  rheumatoid arthritis; RANKL =  receptor activator of 
NF-kappaB ligand; TGF =  transforming growth factor; TLR =  Toll-like receptor; TNF =  tumor necrosis factor.
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Table 1
Models of arthritis
Model Abbreviation Speciesa Feature IC T cell References
Trigger-induced models
Non-specific immune stimuli 
Adjuvant-induced arthritis AA Lewis rat Autoimmune + [1,2]
Oil-induced arthritis OIA DA rat Autoimmune - + [3]
Pristane-induced arthritis PIA DA rat Autoimmune - + [4,5]
Cartilage directed autoimmunity
Collagen-induced arthritis CIA DBA mouse CII AI + + [6,7]
Proteoglycan-induced arthritis PGIA Balb/c mouse PG AI + + [8,9]
Infectious agents/exogenous triggers
Streptococcal cell wall arthritis SCW-A Lewis rat Persistent bacteria AI - + [10]
Flare SCW-F Mouse Th1 7 - + [11]
Antigen-induced arthritis AIA Rabbit, mouse Persistent antigen + + [12,13]
Flare AIA-F Mouse Th17 - + [14]
Transgenic spontaneous models
HTLV-induced arthritis HTLV Mouse Viral tax antigen - + [15]
KRN arthritis KRN K/BxN mouse GPI AI + + [16,17]
SKG arthritis SKG Mouse ZAP-70 T cell defect - + [18,19]
GP130 arthritis GP130 Mouse STAT3, T cell defect - + [20,21]
TNF transgenic arthritis TNFtg Mouse TNF overexpression - - [47,48]
IL-1ra transgenic arthritis IL-1ra-/- Balb/c mouse Autoimmune T cells ± + [23]
IL-1 transgenic arthritis IL-1tg Mouse IL-1 overexpression - - [22]
Immune complex models
Collagen type II CAIA DBA mouse Mouse CII antibody + - [26,27]
KRN serum GPI Balb/c mouse Mouse GPI antibody + - [31]
Poly-L-lysine-lysozyme PLL-L DBA mouse Cationic antigen + - [28]
aMost commonly used. AI =  autoimmune; CAIA= collagen antibody-induced arthritis; GPI =  glucose-6-phosphate isomerase; IC =  immune 
complexes as an early feature; PG =  proteoglycan.
dominant part in all of these m odels and this feature is a 
major princip le of chronic erosive arthritis. Com m on models 
are summarized in Table 1 (see also [1-15] for further reading), 
but only novel developm ents are now discussed in more 
detail. A lthough T cell-directed therapy in RA was question­
able for a while, insight into T cell subclasses has grown and 
more subtle targeting of CTLA4 on T cell subsets looks 
promising. The recent discovery of Th17 as a distinct, 
pathogenic T cell subset further boosted the interest in T cell- 
driven arthritis models.
KRN arthritis
An intriguing, novel arthritis model emerged from experiments 
in transgenic mice overexpressing a self-reactive T cell 
receptor. K/BxN mice, which express both the T cell receptor 
transgene KRN  and the M H C  class II molecule Ag7, develop 
arthritis [16]. In principle, many insults or adjuvants that skew 
regulation of T cell tolerance have the potential to create 
autoimmune pathology, including jo int inflammation. The 
major breakthrough and beauty of the KRN model is the 
elucidation of the driving antigen and the identification that
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passive transfer w ith antibodies induces protracted arthritis. 
In this model, the T cell receptor recognizes the ubiquitous 
self-antigen glucose-6-phosphate isomerase (GPI) and p ro­
vokes, through B cell differentiation and proliferation, high 
levels of anti-GPI antibodies. These antibodies are directly 
pathogenic upon transfer and appear to recognize endoge­
nous cationic GPI, which seems to associate preferentially 
w ith the cartilage surface [17]. The latter may underly the 
dominance of jo int pathology in these mice, although GPI is 
also abundant at other sites in the body. This principle was 
already identified in AIA in mice, where antigen is planted in 
the knee jo int of immunized mice. Cation icity of the antigen 
and sticking to cartilage greatly enhances arthritogenicity 
[13], dem onstrating that either cartilage itself (for example, 
autoimmunity to collagen type II or proteoglycans) or antigens 
tightly associated w ith cartilage are major drivers of this. In 
KRN arthritis, IgG1 antibodies are the major subclass and 
cause a sustained, erosive arthritis after continued transfer, 
w ith high sensitivity in B alb/c mice. The pathology of this 
model is sim ilar to that of passive C IA (CAIA) or IC arthritis, 
w ith planted cartilage-associated antigen, all including IC 
form ation at the cartilage surface. Differences between the 
models relate to the IgG subclasses involved.
SKG and gp130 arthritis
Another recent example of a transgenic T cell model is 
provided by the occurrence of chronic autoimmune arthritis in 
mice w ith a point mutation in the gene encoding ZAP-70, a 
key signal transduction molecule in T cells [18]. The aberrant 
T cell receptor function leads to positive selection of otherwise 
negatively selected autoimmmune T cells. O f high interest, 
these mice fail to develop disease under germ-free conditions 
despite active production of arthritogenic autoimmune cells. 
Apparently, the cells are in a resting state and need further 
activation before trafficking to jo ints and precipitation of 
arthritis occurs. A  single injection of Zymosan provokes 
arthritis in a Dectin-1-dependent but Toll-like receptor (TLR)- 
independent manner [19]. The latter is in sharp contrast with 
the arthritis in IL-1ra-/- mice, which is similarly dependent on 
flora, but clearly TLR4 dependent. Th17 cells play a crucial 
role in SKG  arthritis and identify that environmental factors 
such as yeast may drive or accelerate Th17 arthritis pathology.
M ice w ith a homozygous mutation in the gp 13 0  IL-6 receptor 
subunit show  enhanced signal transduction and STAT3 
activation and develop lymphocyte-mediated RA-like joint 
disease, identifying another example of skewed T cell function 
resulting in arthritis. Increased proliferation of C D 4+  T cells 
appeared due to elevated production of T cell-activating IL-7 
by nonhem atopoietic cells [20,21].
IL-1 transgenic mice and IL-1ra deficient mice
Following the developm ent of human TNF transgenic arthritis 
in the early 1990s, transgenic IL-1 a overexpression was 
shown to induce chronic, destructive arthritis [22]. Trans­
genic mice expressing human IL-1a had high serum levels of
IL-1 and developed severe polyarthritis by 4 weeks of age. 
Hyperplasia of the synovial lining, pannus form ation and, 
ultimately, cartilage destruction were evident. T and B cells 
were scant, but active granulocytes were abundant.
The opposite approach, elimination of IL-1 contro l by gene 
targeting of the endogenous IL-1 receptor antagonist (IL-1ra), 
yielded a T cell model of arthritis. IL-1 ra deficiency in a 
Balb/ca background resulted in pronounced arthritis at the 
age of 8 weeks [23]. Marked synovial and periarticular inflam­
mation was noted, with invasion of granulation tissue and 
articular erosion. Moreover, elevated levels of antibodies 
against immunoglobulins, type II collagen and double-stranded 
DNA were found, suggestive of autoimmune responses. 
Intriguingly, IL-1ra deficiency in a C 5 7B l/6 j background did 
not yield arthritis, but instead showed arteritis. This genetic 
variation, although not well understood, underscores an 
immunologic pathogenic pathway. Overexpression of a range 
of cytokines, including IL-1b, TNF and IL-6, was observed in 
the jo ints before onset of arthritis. Interestingly, autoantibody 
levels did not correlate w ith disease severity, which may imply 
that it reflects a reaction to damaged jo int tissue.
In sharp contrast to the TNF transgenic model, the arthritis in 
IL-1ra-/- mice is dependent on T cells, in line w ith the strong 
genetic restriction. It is consistent w ith the view  that IL-1 is a 
crucial regulator of T cell function. Impaired T cell activation is 
dem onstrated in IL-1 deficient mice, linked to low levels of 
C D 40 ligand and 0 X 4 0  expression on T cells, and underlies 
the suppression of collagen arthritis in IL-1-/- mice. 
Undisturbed IL-1 action, in the absence of IL-1 ra, permits 
activation of IL-17-producing T cells directed against exoge­
nous triggers or endogenous autoantigens. The spontaneous 
arthritis in IL-1ra-/- mice does not develop under germ-free 
conditions and is reduced in TLR4-deficient mice. Both TNF 
and IL-17 deficiency prevent onset of arthritis [24,25].
Immune complex arthritis
Autoantibodies like rheumatoid factor and ACPAs are a key 
feature of RA and the recent success of treatment w ith an 
anti-B cell drug (Rituximab) supports the belief that they have 
a pathogenic role in it. In some of the models, such as 
collagen-, proteoglycan- and antigen-induced arthritis, immune 
complex formation at jo int tissues is a major element of the 
disease. Excessive immune complex formation can cause 
destructive arthritis but chronicity is limited, although it is 
greatly enhanced by T cells. The latter may be linked to the 
need for T cells to sustain antibody production, and the 
greater potential of T cell macrophage interaction to sustain 
jo int pathology. Minute amounts of antigen suffice to stimulate 
T cells, whereas considerable amounts of ICs are needed to 
stimulate inflammatory m ediator release from phagocytes. It is 
likely that IC models mimic part of the RA pathology.
There is grow ing interest in the use of passive IC  models, 
together w ith a range of transgenic knockouts, to identify
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crucial pathways of inflammation and tissue destruction. The 
advantage of passive systems is lower dependence on 
genetic background, avoiding excessive back-crossing to 
create transgenics in suitable, susceptib le mouse strains.
Passive collagen-induced arthritis
Passive transfer of collagen arthritis can be performed w ith a 
critica l mixture of a number of anti-collagen type II 
m onocloclonal antibodies, including com plement binding 
IgG 2a [26,27]. Sets are now commercially available, routinely 
recommending DBA mice as sensitive recipients and 
additional lipopolysaccharide injection fo r synchronization of 
expression. A ccep ted concepts of inflammation pathways 
include IC-mediated com plement activation and Fcgamma 
receptor (FcgR) triggering on phagocytes. Proteoglycan anti­
bodies from the proteoglycan arthritis model can induce 
transient arthritis upon transfer, w ith concom itant pro teo­
glycan loss from the cartilage, but no erosive damage. IgG1 
seems to be the critica l IgG subclass, but its destructive 
potential is not yet clear.
Passive poly-L-lysine-lysozyme arthritis
An IC model emerging from the murine AIA model and using 
the principle of cationic retention involves passive transfer of 
anti-lysozyme antibodies to mice that are locally injected in 
one knee jo int w ith poly-L-lysine-coupled lysozyme. Poly-L- 
lysine-coupled lysozyme is highly cationic and sufficiently 
large to be retained in the jo int for prolonged periods of time. 
Both association w ith synovial tissue and heavy sticking to 
cartilage surfaces contributes to chronicity and cartilage 
destruction. An intriguing observation is the more chronic and 
destructive nature of this arthritis in DBA/1 j com pared to 
B alb/c mice [28], which seems related to high sustained 
levels of activating FcgRs on macrophages of D B A /1 j mice. 
The model shows strong dependence on IL-1, whereas TNF 
blockade was ineffective [29]. FcgRI rather than FcgRIII 
appears to be crucial for cartilage damage [30].
Passive KRN/glucose-6-phosphate isomerase arthritis
Antibod ies present in the serum of arthritic KRN mice are 
directly pathogenic upon system ic transfer. They recognize 
endogenous GPI, which seems to associate preferentially 
w ith the cartilage surface [17 ,31,32]. The latter may underlie 
the dominance of jo int pathology in these mice, although GPI 
is also abundant at other sites in the body and other 
pathologies are noted as well. This observation opened a 
w ide search fo r the relevance of such antibodies in RA, but 
they are not present at high levels and are not found in all 
patients and their role in RA remains to be proven. IgG1 
antibodies are the major IgG subclass in this model and 
cause a sustained, erosive arthritis after continued transfer, 
w ith high sensitivity in B alb/c mice [1]. Large variation is 
noted in the various mouse strains, making it crucial to use 
proper contro l mice w ith a defined genetic background when 
pathway studies are done in particular knockout mice, which 
are often available in mixed genetic backgrounds. Serum is
more active than purified anti-GPI antibodies, suggesting the 
presence of arthritis-prom oting cofactors such as TLR 
ligands or cytokines. Repeat injections enhance chronicity 
and jo int destruction. The model comes close to passive CIA 
and IC  arthritis, w ith planted cartilage-associated antigen, all 
having IC formation at the cartilage surface as a salient 
feature.
Recently, an adaptation of this arthritis model was developed 
by immunization w ith GPI in Freunds adjuvant. This model is a 
mix of IC  and T cell-driven arthritis [33 ,34]. Serum from this 
model was not able to transfer arthritis, indicating that 
antibodies generated w ith this immunization are poorly 
arthritogenic. Upscaling or the use of a critical mixture of 
multiple epitope-recognizing antibodies is needed, sim ilar to 
observations w ith anti-collagen type II antibodies.
Passive citrulline-induced arthritis
In line w ith the identification of AC PAs as an early marker of 
the RA process, many groups have attem pted to induce 
citrulline arthritis. Consensus on whether such antibodies 
occur in classic arthritis models has not yet been reached 
due to inconsistencies in the detection of true A C PAs and 
omission of proper contro ls for antibodies cross-reactive w ith 
non-citrullinated components. In fact, many groups have 
failed to de tect true A C PAs and much of the circumstantial 
evidence fo r them comes from unpublished observations. 
Yet, an initial study supporting the arthritogenic role of anti- 
citrulline immunity in collagen arthritis was provided by Holers 
and colleagues [35]. Intriguingly, mice tolerized to citrulline 
showed reduced collagen arthritis, suggestive of a con tri­
bution of citrulline in CIA, although bystander suppression 
rather than specific  tolerization can not be excluded. In a 
transgenic mouse bearing the human RA-associated shared 
epitope (Dr4), it was subsequently dem onstrated that arthritis 
could be induced by immunization w ith citrullinated fibrinogen 
[36], but the arthritis was different from RA or classic CIA. 
Very recently, Holm dahl's group generated a range of 
antibodies specific  fo r citrullinated collagen type II and 
showed induction of arthritis upon transfer [37]. In addition, 
the antibodies could amplify sm oldering collagen arthritis. 
This amplifying principle was also found in the past for 
rheumatoid factor. The difficulty of showing arthritogenic 
potential and the need for mixtures of antibodies to facilitate 
arthritis expression may explain why antibodies can be 
already detected 5 years before the onset of RA. Epitope 
spreading [38] and the creation of a critica l mix of antibodies, 
allowing the generation of large polyclonal IC  networks, m ight 
be crucial.
IgG, Fcgamma receptors and complement
ICs interact w ith macrophages and granulocytes mainly 
through FcgRs. In this decade FcgRIIb was identified as an 
inhibitory receptor, regulating the activity of the activating 
FcgRI and FcgRIII. Deletion of the IIb receptor renders H-2b 
mice susceptib le to collagen arthritis [39]. Likewise, it was
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shown that DBA-1 j and B10RIII mice, which are highly 
susceptib le to CIA, have a skewed FcgR balance compared 
to non-susceptible C 57B l and B alb/c mice [28]. DBA mice 
have high levels of the stimulatory type III receptor on resting 
m acrophages whereas cells from B1 0RIII mice have normal 
levels but show  skew ing in favor of type III over type IIb 
receptors upon triggering w ith inflammatory stimuli. This 
argues that mice and individuals have different susceptib ilities 
to IC  arthritis dependent on the ir FcgR make up.
A  com plicating factor in extrapolating data from mouse to 
human is the fact that human cells have another dominant 
activating type receptor, FcgRIIa. A  transgenic mouse was 
generated bearing human FcgRIIa. Intriguingly, this mouse 
develops spontaneous multisystem autoimmune disease, 
including arthritis w ith aging [40]. In addition, these mice 
develop CIA more rapidly and show  a severe phenotype. O f 
interest, antagonists developed for this activating FcgRIIa 
showed therapeutic efficacy in CIA in these mice [41].
A  recent discovery in this field is the identification of a novel 
receptor, FcgRIV. Its contribution to jo int pathology remains 
to be studied. For further reading, a review by Boross and 
Verbeek is recommended [42].
Apart from triggering of FcgRs, complement activation plays a 
major role in IC-mediated arthritis. Both the classic and 
alternative pathways of complement activation can contribute 
[43], the relative contributions of which are probably mainly 
dependent on the subclasses of antibodies present, adher­
ence to jo int surfaces as well as the genetic background of 
the mice [1 7]. More recently, a major amplifying role of the 
alternative pathway was identified in the passive CIA model 
performed in a series of mice genetically deficient in 
com ponents of the complement pathways [44]. Intriguingly, a 
novel selective inhibitor of the alternative complement pathway 
markedly reversed inflammation and bone destruction [45].
Role of cytokines
Findings on the involvement of TNF, IL-1, IL-6 and IL-17 in 
arthritis and concom itant jo int destruction will be discussed 
below  in more detail. In general, TNF is a major m ediator in 
the early stages of jo int inflammation in every experimental 
arthritis model. A lthough IL-1 is not a dominant early inflam­
matory cytokine in all models, it is the pivotal cytokine in 
inhibition of chondrocyte proteoglycan synthesis in the 
articular cartilage in all m odels studied so far and blocking of 
it has great beneficial impact on net cartilage destruction 
[46]. In line w ith this, chronic destructive arthritis could not be 
induced in IL-1 deficient mice using any of the classic arthritis 
m odels and this holds as well fo r the more novel m odels such 
as KRN and SKG  arthritis and passive GPI/KRN arthritis. In 
fact, both T cell- and IC-driven murine models appear IL-1 
dependent. In contrast, TNF deficiency reduced the inci­
dence of autoimmune arthritis expression in most models, but 
once jo ints became afflicted full progression to erosive
arthritis did occur in the full absence of TNF. It is not yet clear 
why IL-1 is such a dominant target in IC- and T cell-driven 
murine arthritis models, whereas a crucial role fo r IL-1 in auto­
immune RA in humans is still questionable or even unlikely. 
The latter statem ent is based on the successful targeting of 
IL-1 w ith IL-1ra in proven IL-1-dependent diseases such as 
Mediterranean fever or gout. The identification of the novel 
T cell cytokine IL-17, its role in arthritis models and the strong 
dependence on IL-1 fo r the generation of Th17 cells in mice, 
but certainly also in humans, provides an even greater 
enigma. This may argue that, in human RA, the contribution of 
IL-1 is overruled, or dom inant pathways besides autoimmune 
IC- and T cell-driven processes play a role and have yet to be 
identified.
TNF/IL-1 involvement
In 1991, Kollias and coworkers provided insight into the 
possible role of TNF in arthritis induction in an elegant series 
of experiments. By introducing into mice a m odified human 
TNF transgene lacking a TNF 3 ' untranslated region involved 
in translational repression of TNF, it was shown that p ro­
nounced TNF overexpression results in chronic polyarthritis 
w ith a 100%  incidence [47]. Hyperplasia of the synovium, 
inflammatory infiltrates in the jo int space, pannus formation, 
and cartilage and bone destruction were observed. Intriguingly, 
a sim ilar form of arthritis also developed in targeted mutant 
mice lacking the 3' AU-rich elements, confirm ing the role of 
these elements in the maintenance of a physiological TNF 
response in the jo int [48]. A  proposed mechanism fo r this is 
the inability of natural anti-inflammatory signals such as IL-10 
to suppress TNF production under these conditions. These 
exciting find ings stim ulated a major search fo r functional 
mutations around TNF production in RA patients. However, 
no clear indications have so far been found. Further investi­
gation of TNF receptor involvement showed a crucial role of 
the p55 type I receptor in mediating TNF pathology, and a 
suppressive role of the p75 type II receptor. This implies a 
dualistic pro-inflammatory and immunosuppressive role for 
TNF and heterogeneity of TNF receptor usage in autoimmune 
suppression versus inflammatory tissue damage [49,50]. 
These observations may provide a rationale fo r future treat­
ment of RA w ith selective anti-TNF receptor instead of anti- 
TNF antibodies.
The TNFtg model gained much interest and is now used in 
many labs to identify downstream pathways of TNF-induced 
jo int pathology and to screen the efficacy of various TNF- 
directed therapies. It is not surprising that anti-TNF treatment 
blocks the pathology, but it is a remarkable observation that 
IL-1 is a major downstream mediator. C rosses between 
TNFtg and IL-1 deficient mice yielded insight into IL-1 - 
dependent elements and it was convincingly demonstrated 
that TNF drives inflammation. However, bone erosion is partly 
dependent on IL-1 and cartilage erosion is completely 
dependent on it [51]. It identifies that even in a fully TNF- 
driven system, IL-1 is solely responsible for cartilage erosion
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and this aspect needs further attention in clinical trials. Joint 
erosion scores are often dominated by bone erosion, 
whereas jo int space narrowing, if included, is an insensitive 
measure of focal cartilage erosion and the impact of IL-1 
blocking may be underestimated.
As already mentioned above, in many IC- or T cell-driven 
arthritis models TNF is important at onset of disease, but less 
involved at later stages, when IL-1 and IL-17 become major 
players. This is found in C IA [52 ,53], KRN arthritis [32], SKG 
arthritis [18] and spontaneous arthritis in IL-1 ra-/- mice 
[24 ,25,54 ]. In an attem pt to create a model w ith stronger 
macrophage involvement, yet using natural stimuli, we 
repeatedly in jected streptococcal cell wall fragm ents into the 
murine knee joint, creating chronicity by repeated flares. 
Earlier we showed that such flares can be achieved w ith both 
homologous or heterologous fragm ents [55]. Every flare 
remained TNF dependent in terms of swelling, yet chronic 
infiltrate and concom itant jo int erosion became IL-1 depen­
dent, and the model also displayed a gradually increasing role 
of T cell-derived IL-1 7 and IL-1 7 receptor-bearing synovio­
cytes [11 ,56]. Recently, IL-32 was discovered as a novel 
human cytokine driving TNF expression. It induces arthritis in 
mice [57], but an endogenous murine analog of this cytokine 
has not been found yet, hampering m echanistic studies on its 
role as an upstream mediator.
IL-6/IL-17 involvement
IL-6 has been detected as an abundant cytokine in washouts 
of inflamed jo ints under many experimental model conditions. 
A lthough its function is pleiotropic, therapy was developed 
directed at the IL-6 receptor and humanized anti-IL-6 receptor 
antibodies now appear efficacious in human RA. It is already 
an old observation that AIA and Zym osan-induced arthritis are 
suppressed in IL-6 defic ient mice [58]. Nowadays it is 
becom ing more clear that the underlying mechanism of this 
suppression may be linked to the role of IL-6 in the generation 
of pathogenic Th17 cells. Th17 cells were recently identified 
as a separate T cell lineage, apart from Th1 and Th2 cells, 
and numerous groups have dem onstrated a crucial role for 
IL-6 and IL-1, potentially together w ith transform ing growth 
factor (TGF)P, in their generation [59,60]. IL-23 appears to 
be a propagation factor of Th17 cells, rather than a crucial 
inducing factor. Recent studies show  that blockade of IL-6 
activity w ith anti-IL-6 receptor antibodies suppresses both 
GPI [34] and CIA [61], whereas evidence was obtained of 
reduced Th17 induction. O f interest, th is effect was not noted 
w ith anti-TNF treatment, making IL-6 receptor-d irected 
targeting a potential alternative therapy in patients refractory 
to TNF blockade.
Before the identification of Th17 cells in 2005  as a separate 
lineage, IL-17 was already seen as a novel cytokine displaying 
arthritogenic potential apart from IL-1 and TNF. Local over­
expression using adenoviral IL-17 gene constructs showed 
that it can accelerate inflammation and tissue destruction in
CIA [62], and greatly am plifies passive KRN arthritis [63], 
concom itantly causing accelerated CIA and KRN arthritis 
independent of IL-1 and TNF, respectively. This illustrates that 
arthritis can become refractory to TNF and IL-1 blocking 
when IL-17/Th17 dominates the process. Exploration of the 
efficacy of anti-IL-17 antibodies in arthritis m odels revealed 
suppression of inflammation and tissue damage in C IA [64] 
and superior suppression in T cell-driven flares of AIA com ­
pared to the acute stages of AIA [14]. It also revealed 
suppression of spontaneous arthritis in IL-1ra-/- mice [55], in 
line w ith the absence of this arthritis in IL-17 deficient mice 
[24]. As an exception to the rule, autoimmune proteoglycan- 
induced arthritis appears mainly a Th 1 -mediated model, in 
contrast to most Th17-driven arthritis models. The reason for 
this peculiar phenotype is largely unexplained. It is sup­
pressed but not com pletely prevented in IFNy-deficient mice, 
whereas proteoglycan-induced arthritis could be easily 
elicited in IL-1 7-deficient mice, to demonstrate that severe 
and destructive arthritis can occur independently of IL-17 
[65]. Interestingly, IFNy-deficient mice did not show  complete 
absence of disease, but merely a delayed onset, suggesting 
an early role for Th1 cells in this model. A  role fo r IL-17 in late 
disease was unmasked in IFN /IL-17 double knockouts, 
showing com plete suppression of both early and late arthritis 
(A Finnegan, personal communication).
Impact of environment and co-stimuli
Recently, TLRs were discovered as major receptors involved 
in pattern recognition of bacteria and viruses. Using another 
model of autoimmune inflammation, Luger et al. [66] showed 
that conditions of disease induction affect whether the Th17 
or Th1 effector category is dominant. A fte r immunization w ith 
retinal antigen IRBP in com plete Freund's adjuvant, IL-1 7- 
dependent uveitis develops, whereas induction of 
experimental autoimmune uveitis w ith IRBP-pulsed mature 
dendritic  cells results in the generation of an IFNy-producing 
effector response. The data indicate that the conditions of the 
initial antigen exposure, including the quality/quantity of TLR 
stimulation and/or type of antigen presenting cells, determine 
the dominant e ffector phenotype. Likewise, IL-1 ra-/- mice 
develop spontaneous Th17-dependent arthritis under normal 
housing conditions, but arthritis is completely lost under germ ­
free conditions. This suggests that bacterial flora drive the 
generation of autoimmune Th 17 cells under conditions of 
excess IL-1. Crossing studies with various TLR deficient mice 
identified that TLR4, in particular, was responsible fo r skewing 
towards Th17 responses and development of an erosive 
arthritis phenotype [67]. O f therapeutic interest, TLR4 
blocking, using a receptor antagonist, blocked both IL-1ra-/- 
arthritis as well as CIA [68], identifying TLR4 as a novel target.
As an aside, passive KRN arthritis is IL-1 dependent and is 
greatly reduced in IL-1R deficient mice. Intriguingly, when the 
TLR4 agonist lipopolysaccharide is applied as an additional 
stimulus, IL-1 dependency is overruled and arthritis p ro­
gresses undisturbed [69]. It illustrates that lipopolysaccharide
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stimulation can m imic IL-1 action and IL-1 dependency can 
be lost in the presence of such environmental co-stimuli.
W e  need to be aware that animal models are strongly 
restricted in terms of exposure to environmental triggers 
common to humans due to clean pathogen controlled housing 
conditions. As an example, a link between smoking and 
occurrence of ACPAs has been demonstrated in RA patients, 
a condition not encountered in experimental studies with mice.
Crucial synovial cells
The local architecture of the synovial tissue is of prime 
importance for arthritis expression. W e  showed earlier that 
depletion of synovial lining cells using chlodronate laden 
liposomes prevents expression of arthritis [70], in line w ith a 
major role for these cells in local cytokine and chemokine 
production. A  major development was the identification of 
Cadherin 11 as a crucial factor in the organization of synovial 
architecture. Cadherin 11 defic ient mice have a hypoplastic 
synovial lining, display a disorganized synovial reaction to 
inflammation and are resistant to inflammatory arthritis [71]. 
C adherin -11 therapeutics prevent and reduce arthritis in 
mice. Apart from synovial lining cells, the presence of mast 
cells makes a jo int vulnerable to arthritis expression. Mast cell 
deficient mice lose susceptib ility to passive GPI arthritis, 
identifying mast cell activation and concom itant IL-1 release 
as a dominant feature in the precip itation of arthritis at d istinct 
sites [72]. This is in keeping w ith the old observation that 
preferential expression of arthritis occurs at sites that contain 
abundant numbers of mast cells, such as footpads.
Cartilage and bone destruction
Animal m odels are excellent tools to characterize destructive 
pathways. Cartilage damage observed in models ranges from 
a reversible loss of proteoglycans to collagen damage, cell 
death and com plete surface erosion. This underlines that 
arthritic processes can be more or less destructive, 
dependent on the underlying (immune) process and cytokine 
mixture [73]. Collagen breakdown and aggressive cartilage 
loss is predominantly noted in the presence of immune 
complex deposition, whereas milder, more gradual forms of 
damage are seen in models driven by macrophage or T cell 
activation. Large variation in progressive destruction is also 
observed in patients with RA, with the presence or absence of 
autoantibodies (rheumatoid factor, ACPAs) contributing to this.
It was long debated whether proteoglycan loss contributes to 
erosive damage. Elegant studies were performed in ADAM TS4 
and ADAM TS5 knockout mice, which are defic ient in the 
major enzymes involved in the degradation of aggrecan, the 
dominant proteolgycan of articular cartilage. One identified 
the crucial role of ADAM TS5 in early proteoglycan loss in AIA 
[74]. In addition, aggrecan knockin mice were generated with 
a mutation in the major aggrecanase cleavage site, making 
the aggrecan resistant to specific  breakdown. Intriguingly, 
cartilage erosion was not only dim inished in AIA in these
mice, but cartilage repair was stimulated fo llow ing inflam­
mation [75]. This makes ADAM TS5 a prom ising target in RA, 
potentially preventing erosive collagen damage if treatm ent is 
started early enough. The cytokines TNF, IL-1 and IL-17 can 
drive aggrecanase production, but other m ediator systems 
can as well, making enzyme targeting warranted. As an aside, 
experimental osteoarthritis is also markedly reduced in 
ADAM TS5 knockouts [76], identifying a prom ising thera­
peutic target in this disease w ith large unmet medical needs.
Apart from aggrecanases, studies in immune m odels in 
various FcgR knockout mice further identified that FcgRI is 
pivotal in driving IC-mediated cell activation, metallo- 
proteinase activation and concom itant cartilage erosion 
[77-79]. This receptor or its downstream  activation pathways 
provide challenging therapeutic targets. O f great interest, the 
absence of FcgRI blocked cartilage damage, yet had no 
impact on bone erosion. In fact, bone erosion is independent 
of FcgRs. Arthritis in FcgRI, II and III knockouts is pronounced 
and sustained due to defective clearance of ICs and cartilage 
erosion is absent although bone erosion is enhanced, in line 
w ith enhanced cytokine production under these conditions.
Cytokines like TNF, IL-1 and IL-17 cause bone erosion 
through up-regulation of receptor activator of NF-kappaB 
ligand (RANKL), formerly called osteoprotegerin ligand [80]. 
Like cartilage damage, bone erosion may occur uncoupled of 
inflammation. Local gene transfer w ith IL-4 did not suppress 
jo int inflammation, yet markedly reduced cartilage and bone 
destruction in C IA through suppression of RANKL [81]. Like­
wise, in RANKL deficient mice, jo int inflammation continues in 
passive KRN/GPI IC  arthritis, but bone erosion is prevented 
[82]. Similarly, when TNF transgenic mice were crossed with 
c-fos deficient mice, jo int inflammation continued, yet bone 
erosion was fully absent. c-fos mice lack functional 
osteoclasts and in this background TNFtg mice show  a non­
destructive phenotype. In line w ith this, treatm ent with 
osteoprotegerin, which is the natural inhibitor of RANKL, did 
not reduce inflammation in adjuvant arthritis and TNF 
transgenic mice, yet bone erosion was reduced [83].
The above examples identify that inflammation, bone erosion 
and cartilage erosion are separate processes, potentially 
needing selective therapy. Further improvement of therapy, 
including for bone repair, can be achieved w ith the combined 
blocking of cytokines and RANKL, together w ith an additional 
bone anabolic stimulus such as parathyroid hormone [84,85]. 
M odels also demonstrate that bone repair is evident when 
inflammation wanes, but cartilage repair is more difficu lt to 
achieve and is often defective. Anabolic stimulation and 
tissue engineering approaches are needed when structural 
damage is too far advanced
A  final remark regards bone erosion versus bone apposition. 
Unlike the situation in RA patients, many arthritis models 
show  bone erosion but also pronounced new bone formation
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at the jo int margins. Adjuvant arthritis in the rat is the most 
prom inent example, characterized by major bone apposition 
early in the process, w ith limited to no cartilage erosion in the 
beginning and inflammation as well as bone erosion 
predominantly located in the bone m arrow areas; however, 
KRN arthritis and CIA also show  pronounced bone 
apposition. This apposition is less in arthritis in IL-1ra-/- mice 
and virtually absent in TNFtg mice, both m odels showing a 
gradual but slow  progression of arthritis. O f great interest, a 
TNF-inducible regulator of bone apposition, Dickkopf-1 (DKK- 
1), was recently identified [86]. By inhibiting DKK-1, a 
regulatory molecule of the W n t pathway, the bone destructive 
pattern was inhibited in TNFtg mice and reversed to a bone 
form ing pattern, resembling osteoarthritis. This m ight indicate 
that most murine arthritis m odels are relatively devoid of TNF 
com pared to human RA. O f interest, we have identified TGFp 
as a major driver of osteophytes in experimental osteoarthritis 
[87]. TGFp levels are high in both experimental osteoarthritis 
and RA models, suggesting that the balance between it and 
other regulators such as DKK-1 is important.
Conclusion
M odels are tools that mimic aspects of human disease. It is 
clear that animal models have contributed considerably to 
further our understanding of arthritic processes and conco­
mitant cartilage and bone destruction, and have provided 
novel insights and treatm ent targets. However, final proof of 
the use of data determ ined using these m odels lies in clinics; 
time will tell whether model data are predictable for certain 
targets and, as such, clinical data will help shape and define 
the models. TNF and IL-6 are good examples of molecules 
w ith general pro-inflammatory roles that were identified in 
various models and against which targeted therapies with 
antibodies have shown consistent efficacy in human RA. 
RANKL also seems to fit into this category, w ith a consistent 
role in bone erosion in many conditions. IL-17 seems a 
prom ising target, and we await further identification of its role 
in subgroups of RA w ith a d istinct T cell signature. Increasing 
support fo r a pathogenic role of autoantibodies in RA has 
shifted the interest of researchers to passive IC  models such
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as KRN serum transfer or passive C IA (collagen II antibody 
transfer). Their use is biased by ease of induction. In addition, 
it remains a concern that these m odels are strongly IL-1 
dependent whereas the role of IL-1 in RA patients seems 
limited to destructive processes.
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